Posted by Michael Wonder on 22 Nov 2016
Allergan announces receipt of additional Health Canada approval for Fibristal
21 November 2016 - Allergan announced that it has received an additional approval from Health Canada for Fibristal (ulipristal acetate, 5 mg) for the intermittent treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age.
Each treatment course is three months, given in repeated courses.
